Bio-Rad Laboratories, a US-based distributor of life science research and clinical diagnostics products, will soon launch a new point-of-care HbA1c platform called `in2it' to help physicians instantly analyze and obtain a1c value for patients visiting to their labs.
Talking to Pharmabiz, its country head Dhiren Wagle claimed that the new point of care HBA1c would also improve the doctors' ability significantly to manage diabetes related problems and to diagnose them properly.
The company is also mulling to renew its collaboration with the Institute of Chemical Technology (ICT), Mumbai to provide an application and with Bio-Pharma industries, supporting their chromatographic needs. They can use this facility to optimize their purification protocols for their biomolecules. This optimization process will lead to significant cost savings in this sector, he said.
Besides, company is showing more interest in the field of R&D. "Each year, Bio-Rad invests 10 per cent of its sales in research and development. Its ambition, based on advances in research, is to provide its customers with the materials, techniques and reagents most adapted to their specific needs" added Wagle.
He revealed that a number of R&D work for the upgraded form of the systems such as SELDI, XPR and the Multiplex Protein Array System had been running in to the organization and in the coming months company would be available with its new research based products in both life science and clinical diagnostics section.
Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network operations and has been working in Indian market for more than 10 years.